Daniel Ford

Genesis HealthCare — United States

Medicine · Health Sciences

25h-index4.6kcitations67works40.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(30), Prostate Cancer Diagnosis and Treatment(16), Radiopharmaceutical Chemistry and Applications(13), Advanced Radiotherapy Techniques(9), Cancer Treatment and Pharmacology(9)

Publications63 total

Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomes
Clinical and Translational Radiation Oncology·2025Open Access
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
New England Journal of Medicine·2024· 174 citedOpen Access
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial
European Urology·2024· 47 citedOpen Access
The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC)
Cancers·2024· 7 citedOpen Access
Clinical and patient-reported outcomes of fully adaptive MR-guided stereotactic radiotherapy to prostate: Real-world experience from the UK.
Journal of Clinical Oncology·2024
5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer
International Journal of Radiation Oncology*Biology*Physics·2023· 49 cited
PO-1541 Stereotactic MRguided adaptive radiotherapy in prostate cancer:Real life experience of 180 patients
Radiotherapy and Oncology·2023
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
Journal of Clinical Oncology·2023· 31 cited
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
The Lancet Oncology·2022· 281 citedOpen Access
<scp>TUXEDO</scp> : a phase I/ <scp>II</scp> trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer
British Journal of Urology·2022· 4 citedOpen Access
Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
BJUI Compass·2022· 4 citedOpen Access
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
PLoS Medicine·2022· 112 citedOpen Access
Urine DNA for monitoring chemoradiotherapy response in muscle‐invasive bladder cancer: a pilot study
British Journal of Urology·2021· 4 citedOpen Access
OC-0289 Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy)
Radiotherapy and Oncology·2021· 4 cited
Vertebral compression fracture rate following stereotactic ablative body radiotherapy for spine oligometastases: a UK experience
Journal of Radiotherapy in Practice·2021· 2 cited
MBCL-52. ENDOCRINE PROFILE AFTER MEDULLOBLASTOMA TREATMENT
Neuro-Oncology·2020Open Access
A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer.
Journal of Clinical Oncology·2020· 2 cited
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
The Lancet Oncology·2019· 519 citedOpen Access
Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer
International Journal of Radiation Oncology*Biology*Physics·2019· 1 cited
PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
Journal of Clinical Oncology·2019· 29 cited
page 1 of 4Next →

Frequent Co-authors

Nicholas D. James(13), Shaun Tolan(10), Olivia Naismith(10), Alison Tree(9), Clare Griffin(9), Emma Hall(9), Anjali Zarkar(9), Peter Ostler(8), John Staffurth(8), Stephanie Brown(8), Stephanie Burnett(8), John Tower(8), H. van der Voet(7), William Chu(6), Suneil Jain(6), Philip Camilleri(6), J. Frew(6), Nicholas van As(6), Mathias Winkler(6), Johann S. de Bono(6)